GSK $30B, Eli Lilly $5B: Pharma's $350B U.S. Onshore Rush as 250% Tariffs Loom

Big pharma is putting cash where a looming policy risk could hit hardest. GlaxoSmithKline (LON:GSK) and Eli Lilly (NYSE:LLY) have both flagged sizable U.S. manufacturing outlays, joining a broader industry push that totals more than $350 billion in pledged domestic investment this decade.

GSK laid out a headline number: $30 billion over five years across research, supply-chain upgrades and new plants. That package includes roughly $1.2 billion to build a next‑generation biologics "flex" factory near Philadelphia aimed at respiratory and oncology medicines. The plan also covers new drug‑substance capacity, device and auto‑injector work, and AI-driven modernisation at sites in Pennsylvania, North Carolina, Maryland and Montana. GSK says it already employs about 15,000 people in the U.S.

Eli Lilly is pitching in with a $5 billion project near Richmond, Virginia, to make monoclonal antibodies and bioconjugates - including support for antibody‑drug conjugates used mostly in oncology. Lilly estimates the build-out will bring about 1,800 construction‑period jobs and roughly 650 permanent manufacturing roles once the plant is up and running; the company also claims each dollar of investment could multiply local economic activity several times over. Operations are slated to begin within five years.

Why now? Washington is actively examining pharmaceutical‑specific import levies, and there have been public comments that tariffs could escalate up to 250% over an 18‑month horizon. The industry response reads like an insurance policy: move more production stateside to cut exposure to potential import taxes and political crosswinds.

From an equities perspective this is a mixed bag. Big capital programs mean higher fixed costs and upfront cash outflows that can pressure free‑cash‑flow in the near term. At the same time, onshoring can shrink tariff risk, shorten supply chains, and boost demand for specialized contractors and equipment suppliers - winners well beyond the balance sheet of the drugmakers themselves.

Market reaction will depend on what's already priced in. For companies that have signaled prior U.S. expansion plans, these announcements may be shrugged off. For others, fresh multi‑billion commitments are headline‑making and could reset expectations around long‑term margins, R&D footprint and regional economic impact.

There's also a political element: manufacturing jobs are easy to tout on Capitol Hill, and big plants give companies leverage when negotiating on pricing, procurement and regulation. Meaningful onshore capacity for biologics - not just pills - changes the math for supply security and strategic sourcing.

So the story now is less about intent and more about execution: timelines, spend cadence, equipment orders, and hiring. The investments are real and large. Whether they blunt the tariff threat - or simply raise the cost base for global operations - remains the open question.